These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39141072)

  • 21. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
    Chong L; Jiang YW; Wang D; Chang P; Xu K; Li J
    J Nanobiotechnology; 2023 Oct; 21(1):401. PubMed ID: 37907987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tannins in Terminalia bellirica inhibits hepatocellular carcinoma growth via re-educating tumor-associated macrophages and restoring CD8
    Chang Z; Zhang Q; Hu Q; Liu Y; Zhang L; Liu R
    Biomed Pharmacother; 2022 Oct; 154():113543. PubMed ID: 36057223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.
    Li A; Ji B; Yang Y; Ye B; Zhu Q; Hu X; Liu Y; Zhou P; Liu J; Gao R; Zhou Q; Kang B; Jiang Y
    Front Immunol; 2023; 14():1164448. PubMed ID: 37383234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
    Gao J; Liang Y; Wang L
    Front Immunol; 2022; 13():888713. PubMed ID: 35844605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Streptococcus virulence protein PepO triggers anti-tumor immune responses by reprograming tumor-associated macrophages in a mouse triple negative breast cancer model.
    Liu B; Huang J; Xiao J; Xu W; Zhang H; Yuan Y; Yin Y; Zhang X
    Cell Biosci; 2023 Nov; 13(1):198. PubMed ID: 37925462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
    Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
    Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
    Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
    Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophage Polarization Contributes to the Anti-Tumoral Efficacy of Mesoporous Nanovectors Loaded with Albumin-Bound Paclitaxel.
    Leonard F; Curtis LT; Ware MJ; Nosrat T; Liu X; Yokoi K; Frieboes HB; Godin B
    Front Immunol; 2017; 8():693. PubMed ID: 28670313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy.
    Cheruku S; Rao V; Pandey R; Rao Chamallamudi M; Velayutham R; Kumar N
    Int Immunopharmacol; 2023 Mar; 116():109569. PubMed ID: 36773572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy.
    Gong Y; Gao W; Zhang J; Dong X; Zhu D; Ma G
    J Nanobiotechnology; 2024 Jun; 22(1):341. PubMed ID: 38890636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodegradable mesoporous nanocomposites with dual-targeting function for enhanced anti-tumor therapy.
    Gao S; Liu Y; Liu M; Yang D; Zhang M; Shi K
    J Control Release; 2022 Jan; 341():383-398. PubMed ID: 34863841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy.
    Li C; Wang L; Li Z; Li Z; Zhang K; Cao L; Wang Z; Shen C; Chen L
    Int J Pharm; 2024 Feb; 651():123729. PubMed ID: 38142016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
    Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
    ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional Gadofullerene Nanoparticles Trigger Robust Cancer Immunotherapy Based on Rebuilding an Immunosuppressive Tumor Microenvironment.
    Li L; Zhen M; Wang H; Sun Z; Jia W; Zhao Z; Zhou C; Liu S; Wang C; Bai C
    Nano Lett; 2020 Jun; 20(6):4487-4496. PubMed ID: 32407113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma.
    Han S; Bao X; Zou Y; Wang L; Li Y; Yang L; Liao A; Zhang X; Jiang X; Liang D; Dai Y; Zheng QC; Yu Z; Guo J
    Sci Adv; 2023 Jul; 9(29):eadg2697. PubMed ID: 37467325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIM65 knockout inhibits the development of HCC by polarization tumor-associated macrophages towards M1 phenotype via JAK1/STAT1 signaling pathway.
    Jiang M; Wang D; Su N; Lou W; Chen Y; Yang H; Chen C; Xi F; Chen Y; Deng L; Tang X
    Int Immunopharmacol; 2024 Feb; 128():111494. PubMed ID: 38218012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered macrophage-derived cellular vesicles for NIR-II fluorescence imaging-guided precise cancer photo-immunotherapy.
    Lin Q; Wang Y; Wang L; Fan Z
    Colloids Surf B Biointerfaces; 2024 Mar; 235():113770. PubMed ID: 38330689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting tumor-associated macrophages in the tumor microenvironment.
    Zhou K; Cheng T; Zhan J; Peng X; Zhang Y; Wen J; Chen X; Ying M
    Oncol Lett; 2020 Nov; 20(5):234. PubMed ID: 32968456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
    J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.